Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Inclusion Criteria: * 1\. Aged between 18 and 75 years; * 2\. Lung adenocarcinoma; * 3\. The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy * 4 .The patient is able to understand and comply with the study and has provided written informed consent. Exclusion Criteria: * 1\. Patients with a history of lung surgery; * 2\. Postoperative pathology showed non-primary lung cancer; * 3\. Patients with a history of other tumors; * 4\. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis); * 5\. Unable to cooperate with the researchers because of dementia or cognitive decline * 6\. Other situations that are not in conformity with the standards and requirements of this trial.